Condition: Hereditary Hemorrhagic Telangiectasia · Pulmonary Arterial Hypertension · Sponsor: Diagonal Therapeutics, Inc.
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with hereditary hemorrhagic telangiectasia (HHT). The study consists of three parts: Part A (dose escalation): Single ascending subcutaneous doses of DIAG723 are evaluated in sequential cohorts to assess safety, tolerability, and pharmacokinetics. Part B (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT to assess safety and preliminary efficacy. Part C (dose expansion): Multiple doses of DIAG723 administered over 13 weeks are evaluated in patients with HHT and concomitant pulmonary arterial hypertension to assess safety and exploratory clinical effects in this population. Participants will be randomized within each study part to receive DIAG723 or placebo. The study includes dose escalation in Part A and dose expansion in Parts B and C.
This description comes directly from the study's public registry record.
Diagonal Therapeutics · 339-233-4291 · clinicalinfo@diagonaltx.com
Always discuss trial participation with your own doctor first.
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Not Yet Recruiting |
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Recruiting |
| Doherty Clinical Trials | East Melbourne, Victoria, Australia | Recruiting |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | Not Yet Recruiting |
| New Zealand Clinical Research - Auckland | Grafton, Auckland, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07623525